| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PSM; FGCP; FOLH; GCP2; PSMA; mGCP; GCPII; NAALAD1; NAALAdase |
| WB Predicted band size | 84 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human FOLH1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于FOLH1(PSMA)抗体的代表性文献，按研究领域分类整理：
---
1. **文献名称**：*"Prostate-specific membrane antigen (PSMA) as a target for prostate cancer imaging and therapy"*
**作者**：Bander NH, et al.
**摘要**：该研究综述了PSMA(FOLH1)作为前列腺癌靶点的应用，重点讨论了基于抗体的分子探针(如J591抗体)在肿瘤显像和放射免疫治疗中的潜力，证实其特异性结合能力及临床转化价值。
---
2. **文献名称**：*"Development and validation of a novel monoclonal antibody for the detection of FOLH1 in aggressive prostate cancer"*
**作者**：Chang SS, et al.
**摘要**：研究团队开发了一种高特异性的抗FOLH1单克隆抗体，并通过免疫组化验证其在区分前列腺癌侵袭性亚型中的应用，证明其作为病理诊断标志物的可靠性。
---
3. **文献名称**：*"Antibody-drug conjugates targeting PSMA in metastatic castration-resistant prostate cancer"*
**作者**：Petrylak DP, et al.
**摘要**：该临床试验评估了靶向FOLH1的抗体药物偶联物(如PSMA-ADC)在去势抵抗性前列腺癌中的疗效，结果显示抗体介导的药物递送显著抑制肿瘤生长并延长患者生存期。
---
4. **文献名称**：*"Structural basis of FOLH1 recognition by therapeutic antibodies for cancer therapy"*
**作者**：Lv G, et al.
**摘要**：通过冷冻电镜解析了抗FOLH1抗体(如mAb 7E11)与抗原的结合表位及结构机制，为优化抗体亲和力和开发双特异性抗体提供了分子基础。
---
**领域覆盖**：诊断标志物验证、抗体工程、靶向治疗、结构生物学
**提示**：若需扩展至特定应用(如神经疾病中的FOLH1研究)，可补充相关文献。
Folate hydrolase 1 (FOLH1), also known as prostate-specific membrane antigen (PSMA), is a transmembrane glycoprotein primarily expressed in prostate epithelial cells. It functions as a glutamate carboxypeptidase, hydrolyzing folate polyglutamates to release folate monoglutamates, which are critical for cellular metabolism. FOLH1 gained prominence as a biomarker due to its overexpression in prostate cancer cells, particularly in advanced or metastatic disease, making it a key target for diagnostic and therapeutic applications.
FOLH1 antibodies are immunological tools designed to detect or target this protein. In diagnostics, FOLH1 antibodies are used in immunohistochemistry (IHC) to assess prostate cancer progression and in imaging techniques (e.g., PSMA-PET scans) to locate metastatic lesions. Therapeutically, they form the basis of antibody-drug conjugates (ADCs) and radioligand therapies (e.g., ¹⁷⁷Lu-PSMA-617) that selectively deliver cytotoxic agents to FOLH1-positive cells.
Beyond prostate cancer, FOLH1 is explored in other cancers (e.g., glioblastoma) due to its vascular endothelial expression in tumor neovasculature. However, its physiological roles in the nervous system and small intestine remain less understood. Antibodies targeting FOLH1 must balance specificity to avoid off-target effects, given its low-level expression in healthy tissues. Ongoing research focuses on optimizing antibody engineering to enhance clinical efficacy and safety.
×
